Clinical Trials Browser

Recurrence × blinatumomab × 30 days × Clear all

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma